spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Oral Cancer 

 HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 17 Oct 2019
World-Renowned Cancer Leader Brian Leyland-Jones Named Chairman of NED Biosystems' Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Biopharmaceuticals Oncology Drug Delivery
 HSMN NewsFeed - 21 Dec 2018
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Nov 2018
OncoSec Appoints Robert Ward to its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 4 Sep 2018
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Aug 2018
Vigilant Biosciences Names William Brodie as Chief Executive Officer
Diagnostics Oncology Personnel
 HSMN NewsFeed - 30 Jul 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 5 Dec 2017
OncoSec Announces Promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Oct 2017
OncoSec Presents Positive Phase 2 Data for ImmunoPulse(R) IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Nov 2016
Vigilant Biosciences Announces New Distribution Partnership Agreements for OncAlert(R) Oral Cancer Product Line for Spain, Portugal and Germany
Diagnostics Oncology Distribution
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Oct 2016
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT(R) (sunitinib) Extended Disease Free Survival After Surgical Removal
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2016
OncoSec Appoints Sharron Gargosky, PhD, to Chief Clinical and Regulatory Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 23 May 2016
OncoSec Announces $10 Million At-The-Market Registered Direct Offering
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 17 Nov 2015
Vigilant Biosciences Announces Distribution Agreements for OncAlert(TM) Oral Cancer System for Czech Republic and Slovakia, Israel and Baltic Region
Diagnostics Oncology Distribution
 HSMN NewsFeed - 16 Nov 2015
Vigilant Biosciences Receives CE Mark for OncAlert(TM) Oral Cancer CD44/Total Protein LAB Test to Aid in Diagnosis of Oral Cancer
Diagnostic Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2015
OncoSec Medical Appoints Joann V. Lofgren as Vice President of Market Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Sep 2014
Navidea’s Lymphoseek(R) Recommended by CHMP for European Approval in Sentinel Lymph Node Detection for Melanoma, Breast and Certain Head and Neck Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Sep 2014
OncoSec Medical Appoints Dr. Mai H. Le to Position of Chief Medical Officer and Names Dr. Robert H. Pierce as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jun 2014
Navidea Biopharmaceuticals’ Lymphoseek(R) (technetium Tc 99m tilmanocept) Injection Demonstrates Preferential Accumulation in Tumor-Positive Sentinel Lymph Nodes in Post-Hoc Analysis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2014
Navidea Biopharmaceuticals Expands Lymphoseek(R) Global Commercialization Efforts
Biopharmaceuticals Radiology Distribution
 HSMN NewsFeed - 10 Dec 2013
FDA Grants Fast Track Designation to Navidea Biopharmaceuticals’ Lymphoseek(R) for Sentinel Lymph Node Detection in Patients with Head and Neck Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 20 Jan 2010
Medco to Advance Cancer Care with Personalized and Specialized Treatment for Oncology Patients
Biopharmaceuticals Personalized Medicine Oncology
 HSMN NewsFeed - 17 Sep 2009
Michelson Diagnostics Awarded CE-Mark for Clinical Use of Its VivoSight OCT Scanner in Europe and for Non-Clinical Applications Worldwide
Devices Diagnostics Monitoring Oncology Regulatory
 HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jul 2009
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2008
Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from Health Canada for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2008
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 7 Apr 2008
Thalidomide Pharmion(R) Receives Marketing Approval from Australian Therapeutic Goods Administration for Treatment of Newly Diagnosed Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Nov 2007
Cancer Drug REVLIMID(R) Receives Recommendation for Approval from Australian Drug Evaluation Committee for Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 1 Oct 2007
Zila Adds David Goldman to Board of Directors
Devices Diagnostics Oncology Personnel
 HSMN NewsFeed - 4 Sep 2007
Oral Cancer Drug REVLIMID(R) Receives Swissmedic Approval in Switzerland for Treatment of Multiple Myeloma
Biopharmaceuticals Regulatory Oncology
 HSMN NewsFeed - 22 Aug 2007
Novalar Appoints Steven J. Semmelmayer to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Aug 2007
Zila Takes Steps to Restructure Its Business
Devices Oncology
 HSMN NewsFeed - 1 Aug 2007
Zila Announces CFO Management Change
Diagnostics Oncology Personnel
 HSMN NewsFeed - 19 Jun 2007
REVLIMID(R) Granted Full Marketing Authorization for Treatment of Multiple Myeloma in the European Union
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 May 2007
Zila Appoints Dr. George J. Vuturo to Its Board of Directors and Audit Committee
Devices Diagnostics Oncology Personnel
 HSMN NewsFeed - 22 May 2007
Zila Appoints David R. Bethune as Chairman of Board of Directors
Diagnostics Oncology Personnel
 HSMN NewsFeed - 5 Apr 2007
New Device from LED Dental May Allow Earlier Detection of Oral Cancer
Devices Diagnostics Oncology Dental
 HSMN NewsFeed - 23 Mar 2007
Oral Cancer Drug REVLIMID(R) Receives Positive Opinion for Treatment of Multiple Myeloma From European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Mar 2007
Zila, Inc. Names Lawrence A. Gyenes Chief Financial Officer
Devices Diagnostics Personnel
 HSMN NewsFeed - 18 Dec 2006
Zila, Inc. Announces Resignation of Andrew Stevens, Chief Financial Officer
Diagnostics Oncology
 HSMN NewsFeed - 29 Nov 2006
Zila Transitions to Cancer Detection Company
Devices Diagnostics Oncology
 HSMN NewsFeed - 31 Oct 2006
Prominent Oncologist, Dr. David Sidransky, Joins Zila Board
Diagnostics Personnel
 HSMN NewsFeed - 4 Oct 2006
Plexxikon and Roche Enter Partnership to Develop Targeted Cancer Therapeutic Medicine PLX4032
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 May 2006
Dr. Frank J. Bellizzi Appointed President of Zila's Pharmaceutical Division
Biopharmaceuticals Personnel
Return to NewsFeed  

 Additional items found! 11

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 11 additional stories matching:
Oral Cancer
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.